Federal · 119th Congress
Expedited Access to Biosimilars Act
Policy areaHealth
The Congressional Research Service has not published a summary of this measure.
Read the text of the bill →Sponsor
Cosponsors2
Other titles2
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.Official Title as Introduced
Expedited Access to Biosimilars ActShort Title(s) as Introduced
Legislative history2
Jul 14, 2026
HouseReferred to the House Committee on Energy and Commerce.
Jul 14, 2026
IntroducedIntroduced in House